Exact SciencesEXAS
About: Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
Employees: 7,000
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
25% more funds holding in top 10
Funds holding in top 10: 4 [Q1] → 5 (+1) [Q2]
20% more capital invested
Capital invested by funds: $7.87B [Q1] → $9.43B (+$1.57B) [Q2]
11% more first-time investments, than exits
New positions opened: 99 | Existing positions closed: 89
1% less funds holding
Funds holding: 547 [Q1] → 542 (-5) [Q2]
3% less repeat investments, than reductions
Existing positions increased: 173 | Existing positions reduced: 178
3.73% less ownership
Funds ownership: 97.82% [Q1] → 94.1% (-3.73%) [Q2]
46% less call options, than puts
Call options by funds: $57.2M | Put options by funds: $105M
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
6 analyst ratings
BTIG Mark Massaro | 30%upside $60 | Buy Maintained | 12 Aug 2025 |
Piper Sandler David Westenberg | 30%upside $60 | Overweight Maintained | 11 Aug 2025 |
Evercore ISI Group Vijay Kumar | 38%upside $64 | Outperform Maintained | 8 Aug 2025 |
UBS Dan Leonard | 15%upside $53 | Neutral Maintained | 7 Aug 2025 |
RBC Capital Conor McNamara | 1%downside $46 | Sector Perform Maintained | 7 Aug 2025 |
Financial journalist opinion
Based on 18 articles about EXAS published over the past 30 days
